MedPath

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed
Conditions
Generalised Tonic-Clonic Seizures
Idiopathic Generalized Epilepsy
Partial Onset Seizures
Interventions
Registration Number
NCT04252846
Lead Sponsor
Eisai Limited
Brief Summary

The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures \[POS\] with or without secondary generalization \[SG\] or for primary generalized tonic-clonic seizures \[PGTCS\] associated with idiopathic generalized epilepsy \[IGE\] as first adjunctive to antiepileptic drug (AED) monotherapy as part of their routine clinical care.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
191
Inclusion Criteria
  1. Diagnosis of epilepsy
  2. History of POS with or without SG or PGTCS associated with IGE
  3. Documented POS with or without SG or PGTCS associated with IGE, within the past 12 months
  4. Previously treated with 1 or 2 AEDs as monotherapy
  5. At least 4 weeks' seizure diary data, or sufficient clinical detail to calculate baseline seizure frequency
Exclusion Criteria
  1. Episode(s) of status epilepticus within the past 6 months before Screening

  2. Previously treated with 2 or more AEDs in combination (other than during cross-titration between AED monotherapies)

  3. Previous or current use of perampanel

    Note: Retrospective inclusions will be allowed but only if the time between the initiation of perampanel treatment and the inclusion does not exceed 7 calendar days

  4. Hypersensitivity to perampanel or any of the excipients

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PerampanelPerampanelParticipants with a diagnosis of epilepsy (POS with or without SG or PGTCS associated with IGE) will initiate treatment with perampanel as first adjunctive treatment as per the clinical judgment of the treating physician as part of routine clinical care. All participants will be observed prospectively for up to 12 months after initiation of perampanel treatment.
Primary Outcome Measures
NameTimeMethod
Retention Rate at Month 12Month 12

Retention rate at 12 months is defined as the percentage of participants remaining on perampanel at 12 months.

Secondary Outcome Measures
NameTimeMethod
Retention Rate at Month 6Month 6

Retention rate at 6 months is defined as the percentage of participants remaining on perampanel at 6 months.

Pragmatic Seizure-free Rate at Months 6 and 12Months 6 and 12

Pragmatic seizure-free rate is defined as the percentage of participants (based on all study participants) who are free of all seizures at 6 months (and for the previous 3 months) and at 12 months (and for the previous 6 months).

Completer Seizure-free Rate at Months 6 and 12Months 6 and 12

Completer seizure-free rate is defined as the percentage of participants (based on a subset of study participants who remain on perampanel treatment at 6 and 12 months) who are free of all seizures at 6 months (and for the previous 3 months) and at 12 months (and for the previous 6 months), respectively.

Median Percent Change From Baseline in Seizure Frequency at Months 6 and 12Months 6 and 12

Seizure frequency change will be measured at 6 months (averaged over the previous 3 months) and at 12 months (averaged over the previous 6 months).

50 Percent (%) Responder Rate at Months 6 and 12Months 6 and 12

50% responder rate is defined as the percentage of participants with greater than or equal to (\>=) 50% reduction in seizure frequency (averaged over the 3 months before the 6-month visit, and over the 6 months before the12-month visit) relative to baseline.

Seizure Worsening Rate at Months 6 and 12Months 6 and 12

Seizure worsening rate is defined as the percentage of participants with \>=10% increase in seizure frequency (averaged over the 3 months before the 6-month visit, and over the 6 months before the 12-month visit) relative to baseline.

Last Dose of Perampanel at Months 6 and 12Months 6 and 12
Percentage of Participants by Perampanel Dose Titration SpeedUp to Month 12
Duration of Treatment on PerampanelUp to Month 12
Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs),Serious Adverse Events (SAEs), TEAEs Leading to Discontinuation, and TEAEs by SeverityUp to Month 12

Trial Locations

Locations (36)

Sydvestjysk Sygehus Esbjerg

🇩🇰

Esbjerg, South Denmark, Denmark

Hôpital Pontchaillou

🇫🇷

Rennes, Ille-et-Vilaine, France

Hôpital Roger Salengro

🇫🇷

Lille, Nord, France

Centre de consultations Saint-Jean Bâtiment A

🇫🇷

Cagnes-sur-Mer, France

Hopitaux de La Timone

🇫🇷

Marseille, France

Hôpital Robert Debré

🇫🇷

Paris, France

Centre hospitalier de Pau

🇫🇷

Pau, France

Centre Hospitalier Universitaire de Toulouse

🇫🇷

Toulouse, France

CHRU Bretonneau

🇫🇷

Tours, France

Eisai Trial Site #2

🇩🇪

Berlin, Germany

Scroll for more (26 remaining)
Sydvestjysk Sygehus Esbjerg
🇩🇰Esbjerg, South Denmark, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.